Kenvue Faces Near-Term Challenges Amid Autism-Related Concerns

about 1 month ago

Scarlett Fu

"One more. Let's take a look at Kenview. So ticker KVUE. Those shares not doing so hot at the moment, down more than 5% now. And that's because we did get a Washington Post report over the weekend saying that Trump administration officials plan to link the active ingredient in Thai law, which is made by Kenview, to autism. Bloomberg Intelligence saying that if there is any reduced demand for Tylenol as a result of this, then that will make their return to EPS growth this next year more challenging."

Kenvue (ticker KVUE) is under pressure with shares down over 5% due to concerns that a potential regulatory link between its product's active ingredient and autism could depress demand for Tylenol. This negative catalyst, combined with existing lawsuits, may hinder its EPS growth prospects.

Related Stocks